EA202191280A1 - Конструкции для доставки для трансцитоза и связанные способы - Google Patents

Конструкции для доставки для трансцитоза и связанные способы

Info

Publication number
EA202191280A1
EA202191280A1 EA202191280A EA202191280A EA202191280A1 EA 202191280 A1 EA202191280 A1 EA 202191280A1 EA 202191280 A EA202191280 A EA 202191280A EA 202191280 A EA202191280 A EA 202191280A EA 202191280 A1 EA202191280 A1 EA 202191280A1
Authority
EA
Eurasian Patent Office
Prior art keywords
transcytosis
related methods
relates
delivery constructs
methods
Prior art date
Application number
EA202191280A
Other languages
English (en)
Inventor
Амир Порат
Эльберт Сето
Чарльз Олсон
Рэндалл Дж. Мрсни
Тахир Махмуд
Вэйцзюнь Фэн
Салли Постлетуэйт
Original Assignee
Эпплайд Молекьюлар Транспорт Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/en
Application filed by Эпплайд Молекьюлар Транспорт Инк. filed Critical Эпплайд Молекьюлар Транспорт Инк.
Publication of EA202191280A1 publication Critical patent/EA202191280A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Изобретение относится к не встречающимся в природе слитым молекулам, содержащим группы терапевтической полезной нагрузки, такой как IL-22, с носителем. Изобретение также относится к способам и композициям для получения, очистки, рефолдинга, формуляции и введения слитых молекул. Также изобретение относится к способам и применению очищенных молекул для лечения и профилактики заболеваний или расстройств.
EA202191280A 2018-11-07 2019-11-07 Конструкции для доставки для трансцитоза и связанные способы EA202191280A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
US201962888133P 2019-08-16 2019-08-16
US201962888238P 2019-08-16 2019-08-16
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
PCT/US2019/060356 WO2020097394A1 (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods

Publications (1)

Publication Number Publication Date
EA202191280A1 true EA202191280A1 (ru) 2021-12-27

Family

ID=70612266

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191280A EA202191280A1 (ru) 2018-11-07 2019-11-07 Конструкции для доставки для трансцитоза и связанные способы

Country Status (20)

Country Link
US (2) US11027020B2 (ru)
EP (2) EP4083058A3 (ru)
JP (1) JP2022506990A (ru)
KR (1) KR20210110294A (ru)
CN (1) CN113423722A (ru)
AU (1) AU2019377117A1 (ru)
BR (1) BR112021009003A2 (ru)
CA (1) CA3119060A1 (ru)
CL (1) CL2021001209A1 (ru)
CO (1) CO2021007402A2 (ru)
DK (1) DK3650037T3 (ru)
EA (1) EA202191280A1 (ru)
ES (1) ES2911075T3 (ru)
IL (1) IL282987B2 (ru)
MX (1) MX2021005346A (ru)
PL (1) PL3650037T3 (ru)
PT (1) PT3650037T (ru)
SG (1) SG11202104721RA (ru)
TW (1) TW202031678A (ru)
WO (1) WO2020097394A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
SI3762009T1 (sl) 2018-03-08 2023-03-31 Applied Molecular Transport Inc. Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
EP4161943A2 (en) * 2020-06-09 2023-04-12 Icosavax, Inc. Method of making virus-like particle
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
ATE412009T1 (de) * 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
AU2001297988B2 (en) 2000-11-27 2006-10-26 Powderject Vaccines, Inc. Nucleic acid adjuvants
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
AU2002339121B2 (en) 2001-05-23 2007-03-22 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AU2004252169A1 (en) * 2003-06-23 2005-01-06 Genetics Institute, Llc Antibodies against interleukin-22 and uses therefor
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2006135428A2 (en) 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
EP1971367A4 (en) 2005-12-05 2010-04-07 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS
EP2046375B1 (en) * 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
WO2009014650A2 (en) * 2007-07-20 2009-01-29 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009149281A1 (en) 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof
CN107056951A (zh) 2008-10-02 2017-08-18 阿帕特夫研究和发展有限公司 Cd86拮抗物多靶点结合蛋白
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
EP2667898A1 (en) 2011-01-26 2013-12-04 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
DK2726091T3 (da) 2011-06-29 2020-03-09 Rani Therapeutics Llc Præparater med terapeutisk middel til fremføring i et lumen i tarmkanalen ved hjælp af en synkbar anordning til lægemiddelfremføring
SI2970422T1 (en) 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN112386680A (zh) 2013-11-07 2021-02-23 纪念斯隆–凯特林癌病中心 在胃肠道移植物抗宿主病的治疗中使用il-22的方法
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
ES2900328T3 (es) 2014-05-07 2022-03-16 Applied Molecular Transport Inc Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
EP3237441A4 (en) * 2014-12-23 2018-06-06 Armo Biosciences, Inc. Methods of improving yield in recombinant protein production
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
TW201834690A (zh) 2016-12-14 2018-10-01 美商寶珍那提公司 以免疫抑制劑治療胃腸道疾病
PT3762009T (pt) * 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
US20200140511A1 (en) 2018-11-07 2020-05-07 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体

Also Published As

Publication number Publication date
TW202031678A (zh) 2020-09-01
US20210338828A1 (en) 2021-11-04
CA3119060A1 (en) 2020-05-14
IL282987A (en) 2021-06-30
EP4083058A2 (en) 2022-11-02
IL282987B2 (en) 2023-02-01
AU2019377117A1 (en) 2021-06-10
ES2911075T3 (es) 2022-05-17
DK3650037T3 (da) 2022-05-02
EP4083058A3 (en) 2023-01-11
PT3650037T (pt) 2022-06-27
KR20210110294A (ko) 2021-09-07
JP2022506990A (ja) 2022-01-17
CL2021001209A1 (es) 2021-11-19
CO2021007402A2 (es) 2021-09-30
BR112021009003A2 (pt) 2021-08-17
EP3650037A1 (en) 2020-05-13
US11027020B2 (en) 2021-06-08
CN113423722A (zh) 2021-09-21
WO2020097394A1 (en) 2020-05-14
US20200306383A1 (en) 2020-10-01
PL3650037T3 (pl) 2022-06-06
EP3650037B1 (en) 2022-03-02
SG11202104721RA (en) 2021-06-29
MX2021005346A (es) 2021-10-13
IL282987B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
EA202191280A1 (ru) Конструкции для доставки для трансцитоза и связанные способы
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
EA202090817A1 (ru) Триспецифические белки и способы их применения
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA201691576A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2020007628A (es) Composiciones y metodos de uso.
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
IN2014DN03213A (ru)
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2022010193A (es) Moleculas dirigidas a proteina ras.
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.